双重抗血小板治疗用于小卒中和短暂性脑缺血发作。
Dual antiplatelet therapy for minor ischemic stroke and transient ischemic attack.
机构信息
At Presbyterian College School of Pharmacy in Clinton, S.C., Blake Miller is an assistant professor of pharmacy practice and director of interprofessional education and Kayce M. Shealy is an associate professor of pharmacy practice and associate dean of academic affairs. The authors have disclosed no potential conflicts of interest, financial or otherwise.
出版信息
JAAPA. 2022 Dec 1;35(12):10-11. doi: 10.1097/01.JAA.0000892756.17928.30.
Traditional preventive management of patients suffering from a minor ischemic stroke and/or transient ischemic attack indicated dual antiplatelet agents for 90 days. Newer clinical trial data suggest that therapeutic effectiveness is reached much sooner than previous guideline recommendations. Continued use of dual antiplatelet therapy beyond newly studied durations of efficacy has shown an increased risk in hemorrhagic complications with little to no additional preventive benefit. This article highlights newer trial data and recognizes a significant change in therapeutic management for patients suffering a minor ischemic stroke and/or transient ischemic attack.
传统的轻度缺血性卒中和/或短暂性脑缺血发作患者的预防管理建议使用双联抗血小板药物 90 天。新的临床试验数据表明，双联抗血小板治疗的疗效达到时间比之前的指南建议更早。在新研究的疗效持续时间之后继续使用双联抗血小板治疗会增加出血并发症的风险，而几乎没有额外的预防益处。本文强调了新的试验数据，并认识到轻度缺血性卒中和/或短暂性脑缺血发作患者的治疗管理发生了重大变化。
Zotero 插件